Fig. 6From: The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysisAn overview of the safety profile for grade 3–5 adverse events (AEs) in capecitabine and capecitabine-free chemotherapy groupsBack to article page